Mankind Pharma’s IPO Subscription Begins on April 25, with Listing Set for May 9
- ByStartupStory | April 18, 2023
India’s fourth-largest pharmaceutical company in terms of domestic sales and the second-largest in sales volume for the financial year 2022, Mankind Pharma, has announced its initial public offering (IPO). The IPO subscription will open on April 25 and close on April 27, with anchor bidding commencing on April 24. Equity shares will be credited on May 8, and the stock will be listed on exchanges on May 9. Don’t miss out on this opportunity to invest in Mankind Pharma’s IPO.
Mankind Pharma‘s upcoming IPO is a pure offer for sale of up to 40.06 million shares by its existing shareholders and promoters. The offer for sale (OFS) will consist of up to 3.71 million shares by Ramesh Juneja, up to 3.51 million shares by Rajeev Juneja, 2.80 million shares by Sheetal Arora, up to 17.41 million shares by Cairnhill CIPEF Ltd2, up to 2.62 million shares by Cairnhill CGPE Ltd, up to 9.96 million shares by Beige Ltd, and up to 50,000 shares by Link Investment Trust. Get ready to invest in Mankind Pharma’s IPO and take advantage of this unique opportunity.
Mankind Pharma, known for producing well-known brands such as Manforce Condoms, Prega News pregnancy test kits, and Unwanted-72 emergency contraceptives, has the support of private equity firm Chrys Capital and Capital International. The company was founded by Ramesh Juneja and became a fully integrated pharmaceutical company in 1995. Mankind Pharma specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations for acute and chronic therapeutic areas, as well as various consumer healthcare products. Don’t miss out on the chance to invest in this leading pharmaceutical company.
Mankind Pharma places a strong emphasis on the domestic market, with revenue from operations in India accounting for 97.60 percent of its total revenue in the financial year 2022. The pharmaceutical company has developed 36 well-known brands and has one of the largest networks of medical representatives in the Indian pharmaceutical market. Invest in Mankind Pharma’s upcoming IPO and take advantage of their success in the Indian pharmaceutical industry.
Mankind Pharma, in addition to its well-known Manforce Condoms, Prega News, and Unwanted-72 brands, has also expanded into various consumer healthcare categories, including antacid powders (Gas-O-Fast), vitamin and mineral supplements (Health OK brand), and anti-acne preparations (AcneStar brand). Kotak Mahindra Capital, Jefferies, IIFL Capital, Axis Capital, and JP Morgan are the lead managers to the IPO, while Shardul Amarchand Mangaldas, Cyril Amarchand Mangaldas, AZB & Partners, and Sidley Austin are the law firms involved in the deal. Don’t miss out on this opportunity to invest in Mankind Pharma’s diverse range of brands and products through their upcoming IPO.
Calling all entrepreneurs, investors and business owners! The wait is finally over. The 2nd edition of Startup Story B2B Connect is back with a bang – and this time, we’re taking it up a notch. With more startups, more investors and bigger opportunities than ever before, this is your chance to connect, collaborate and take your business to the next level. Get ready for an unforgettable networking experience that’s set to change the game. Stay tuned for all the exciting updates! Register Now Here.
Follow Startup Story
Related Posts
